



FULL-LENGTH PAPER


# Synthesis and antiproliferative activity of pterostilbene and 3'-methoxy pterostilbene Mannich base derivatives against Hela cells

Chongyang Liu<sup>1</sup> · Linpei Dong<sup>1</sup> · Shengchun Wang<sup>1</sup> · Qiu Wang<sup>1</sup>

Received: 27 January 2015 / Accepted: 1 July 2015 / Published online: 11 July 2015  
© The Author(s) 2015. This article is published with open access at Springerlink.com

**Abstract** Fourteen novel pterostilbene (**1**) and 3'-methoxy pterostilbene (**2**) Mannich base derivatives (**3–16**) were synthesized via the microwave-assisted Mannich reaction of **1** or **2** with various secondary amines and formaldehyde. The regioselectivity of the reaction occurred preferentially at C-3' (and/or C-5') position of the B-ring of stilbene. The biological testing results showed that all the target compounds exhibit antiproliferative activity against Hela cells from IC<sub>50</sub> = 22.5–65.3 μM. Compounds **1–3**, **7**, **11–13**, and **16** displayed higher (lower IC<sub>50</sub> values) activity than the positive control cisplatin (IC<sub>50</sub> = 41.3 μM).

## Graphical Abstract



**Keywords** Pterostilbene · 3'-Methoxy pterostilbene · Mannich base derivatives · Synthesis · Antiproliferative activity · Hela cells

**Electronic supplementary material** The online version of this article (doi:10.1007/s11030-015-9615-1) contains supplementary material, which is available to authorized users.


✉ Qiu Wang  
wangqa@hnu.edu.cn

<sup>1</sup> College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, People's Republic of China

## Introduction

Pterostilbene (*trans*-3,5-dimethoxy-4'-hydroxystilbene, **1**), a naturally occurring dimethylether analog of resveratrol, was first isolated from *P. Santalinus* (red sandalwood) and it is also found in several types of berries and grapes [1]. Pterostilbene has been shown to have a cancer chemopreventive effect similar to that of resveratrol and it is cytotoxic to a variety of tumor cell types, such as human gastric carcinoma cells [2], human prostate cancer cells [3], and lung cancer cells [4]. 3'-Methoxy pterostilbene (**2**), a naturally occurring homolog of pterostilbene, was isolated from *Sphaerophysa salsula* [5] and showed higher cytotoxic activities on some cancer cells than resveratrol [6].

Biological activity studies have shown that the development of structural analogs of antitumor agents possessing basic nitrogen atom moiety is of great value [7,8]. Anticancer studies using several classes of polyaromatic antitumor agents indicate that the introduction of a nitrogen-containing side chain increases significantly the biological activity and potency of the parent compounds. For example, it has been shown that the presence of the nitrogen moiety in flavopiridol, a synthetic nitrogen-containing flavonoid with antitumor activity against various tumor cell lines, is critical for its antitumor effect [9]. The Mannich reaction is a commonly used way to introduce nitrogenous moieties, such as aminoalkyl group to phenols. The modification of an aminoalkyl side chain in aromatic substrates permits to increase significantly the biological potency of bioactive molecules due to the greater number of molecular sites for electrophilic attack by cellular constituents, as well as due to the cascade effect of preferential chemosensitization when compared with parent compounds [10]. Furthermore, Mannich bases have been associated with increased water solubility [11].



**Scheme 1** Synthesis of pterostilbene and 3'-methoxy pterostilbene Mannich base derivatives (3–16)

Resveratrol has been the subject of numerous investigations, and its cancer chemopreventive activity has been fully demonstrated [12]. Prompted by the close structural similarity of pterostilbene and resveratrol, as well as the current high interest in the development of a pterostilbene-based therapeutic [13, 14], we decided to synthesize two series of fourteen pterostilbene and 3'-methoxy pterostilbene Mannich base derivatives to be evaluated for their antiproliferative activity against human cervical carcinoma Hela cells by the standard CCK-8 assay.

## Results and discussion

The synthetic route used for the construction of novel pterostilbene and 3'-methoxy pterostilbene Mannich base derivatives (3–16) is shown in Scheme 1. Pterostilbene (1) and 3'-methoxy pterostilbene (2) were synthesized by *O*-methylation, reduction, chlorination, Arbuzov rearrangement, and Wittig reaction using commercially available 3,5-

dihydroxybenzoic acid, 4-hydroxybenzaldehyde, or vanillin as starting material as described previously by our group [15].

Our strategy for the synthesis of the *C*-aminomethylated derivatives relied upon the electrophilic substitution at C-3' and/or C-5' of the stilbene B-ring. This was achieved by the Mannich reaction of 1 and 2 with formaldehyde and secondary amines in methanol, introducing a dialkylaminomethyl group in the *ortho*- position of the phenolic group. The general conditions of the Mannich reaction for the phenol compounds are based on the substrate, the amine, and formaldehyde ratio in alcohol with prolonged heating. It was reported that microwave irradiation can be used for the Mannich reaction because of the considerable advantages over conventional heating, such as substantial rate enhancement cleaner reaction and improvement in yield [16, 17]. In our case, pterostilbene (1) or 3'-methoxypterostilbene (2), formaldehyde, and secondary amines in a 1:1.2:1.2 ratio, respectively, were stirred under microwave irradiation (600 W) for 0.5–2 h in methanol to afford the *C*-aminomethylated derivatives 3–16. The Mannich reaction of pterostilbene (1) with methylpiperazine would lead to a dif-

**Table 1** Half-inhibitory concentration [ $IC_{50}$  ( $\mu$ M)] of compounds **1–16** on the Hela cells

Compounds	$IC_{50}$ ( $\mu$ M)	Compounds	$IC_{50}$ ( $\mu$ M)
<b>1</b>	28.5	<b>10</b>	41.6
<b>2</b>	23.0	<b>11</b>	35.4
<b>3</b>	23.3	<b>12</b>	38.4
<b>4</b>	41.8	<b>13</b>	387
<b>5</b>	42.5	<b>14</b>	43.0
<b>6</b>	50.4	<b>15</b>	65.3
<b>7</b>	28.3	<b>16</b>	36.7
<b>8</b>	57.1	cisplatin <sup>a</sup> (DDP)	41.3
<b>9</b>	50.5		

<sup>a</sup> cisplatin (DDP) was employed as positive control

ferent product at different reaction times where the product was a mono-substituted product (compound **6**, 0.5 h of reaction time) or a double-substituted product (compound **8**, 2 h of reaction time).

The structures of all synthesized Mannich base were confirmed by  $^1\text{H}$ NMR,  $^{13}\text{C}$ NMR, and MS analysis. The  $^1\text{H}$ NMR spectra of compounds **3–9** clearly indicate the absence of the of H-3' proton signal at  $\delta$  6.28 (and H-5' proton for compounds **8**, **9**) in the B-ring of pterostilbene (**1**). Similarly, the H-5' proton at  $\delta$  6.91 of 3'-methoxy pterostilbene (**2**) in the B-ring disappeared for compounds **10–16**. The signal at  $\delta$  3.60–4.10 indicated the presence of the aminomethyl group at C-3' (or C-5') position of compounds **3–16**.

The antiproliferative activity of the pterostilbene (**1**), 3'-methoxypterostilbene (**2**), and the Mannich base derivatives **3–16** was assessed using the CCK-8 [2H-tetrazolium, 5-(2,4-disulfophenyl)-3-(2-methoxy-4-nitrophenyl)-2-(4-nitrophenyl) inner salt, sodium salt (1:1)] assay using the human cervical carcinoma Hela cell line. The results are shown in Table 1. The dose-response curves for the CCK-8 assay of compounds **1**, **2**, **3** and **7** on Hela cells proliferation are shown in Fig. 1. Cisplatin (DDP) was used as positive control. The results show that all the test compounds exhibit moderate to potent antiproliferative activity against Hela cells.

In the series of pterostilbene Mannich bases, our data showed that compound **3**, characterized by a dimethylaminomethyl group in the C-3' position, was found to have an increase in antiproliferative activity ( $IC_{50}$  = 23.3  $\mu$ M) when compared with parent compound pterostilbene (**1**,  $IC_{50}$  = 28.5  $\mu$ M). Compound **7** ( $IC_{50}$  = 28.3  $\mu$ M), which contains a pyrrolidin-1-ylmethyl group substituent on the C-3' position, presented with potency similar to that of parent compound pterostilbene (**1**). Compounds **1**, **3**, and **7** ( $IC_{50}$  range 23.3–28.5  $\mu$ M) showed more potent antiproliferative activity against Hela cells than the positive control cisplatin (DDP) ( $IC_{50}$  = 41.3  $\mu$ M). In the series of 3'-methoxypterostilbene Mannich bases, although the intro-

duction of a dialkylaminomethyl group did not increase the activity compared to its parent compound **2**, compounds **11**, **12**, **13** and **16** exhibited some antiproliferative activity on Hela cells ( $IC_{50}$  range of 35.4–38.7  $\mu$ M) being slightly more potent than cisplatin (DDP) ( $IC_{50}$  = 41.3  $\mu$ M).

The preliminary structure–activity relationship analysis revealed that pterostilbene (**1**) has a moderate antiproliferative activity on Hela cells. The introduction of smaller methoxy or dimethylaminomethyl side chains into the 3'-position of **1** was to increase biological activity, and the introduction of larger dialkylaminomethyl side chain into 3'-position of **1** was to decrease the activity. Based on these observations, the methoxy and dimethylaminomethyl groups were selected as suitable substituents at the 3'-position of **1**. The introduction of all dialkylaminomethyl side chain into 5'-position of 3'-methoxy pterostilbene (**2**) was to decrease the activity. As the antiproliferation assay was carried out in vitro, the inhibitory effect on Hela cell variance among these compounds could be attributed to the hydrophobicity and permeability changes resulting from different substituents and position of side chains in pterostilbene (**1**).

## Conclusion


In Summary, 14 new pterostilbene (**1**) and 3'-methoxy pterostilbene (**2**) Mannich base derivatives **3–16** were synthesized through a microwave-assisted Mannich reaction strategy. All the compounds were tested for their antiproliferative activity against Hela cells using the standard CCK-8 assay; the results indicating that compounds **1**, **2**, **3**, **7**, **11**, **12**, **13** and **16** were slightly more potent than anticancer drug cisplatin (DDP). The pterostilbene skeleton can serve as a promising structural template for the development of novel antiproliferative agents deserving further investigation.

## Experimental

### General information

Melting points were measured on an XRC-I apparatus and were uncorrected. Microwave reactions were performed using an XH-MC-1 microwave reactor (50–900 W) (Beijing Xianghu Science and Technology Development Co., China).  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra were recorded on a Bruker AM-400 instrument, using tetramethylsilane as internal standard (*s* single; *d* doublet; *t* triplet; *q* quartet; *m* multiplet), chemical shifts ( $\delta$ ) in ppm, and coupling constants (*J*) in Hz. Mass spectra were recorded using a VG Autospec-3000 and a ZA-BHS spectrometer (ESI or EI ionization method). Pterostilbene (**1**) and 3'-methoxy pterostilbene (**2**) were synthesized and purified according

**Fig. 1** Dose-response curve of compounds **1**, **2**, **3** and **7** on Hela cell proliferation assay



to our published procedure [15]. Formaldehyde, secondary amines, methanol, ethylacetate, petroleum ether, triethylamine, CCK-8 [2H-tetrazolium, 5-(2,4-disulfophenyl)-3-(2-methoxy-4-nitrophenyl)-2-(4-nitrophenyl) inner salt, sodium salt (1:1)] were obtained from Energy Chemicals. Column chromatography was carried out on silica gel (200–300 mesh). Commercially available AR grade or chemically pure reagents were used. Anhydrous solvents were dried and redistilled prior to their use.

#### General procedure for the synthesis of Mannich base derivatives **3–16**

Compound **1** or **2** (200 mg, 0.78 mmol) was dissolved in methanol (10 mL), then formaldehyde (0.94 mmol) and a secondary amine (0.94 mmol) were introduced to this solution. The reaction mixture was stirred under microwave irradiation (600 W) at 80 °C. The end of the reaction was determined by TLC. When the reaction was complete, the solvent was removed in *vacuo*. The residue was extracted with ethyl acetate (3 × 20 mL) and water (15 mL). The organic phases were combined, washed with H<sub>2</sub>O, and dried over anhydrous sodium sulfate. The solvent was evaporated and resulting crude material was purified by silica gel column chromatography (ethyl acetate:petroleum

ether:triethylamine, *v/v*, 1:9:0.01) to obtain desired products **3–16**.

#### (*E*)-3'-[(Dimethylamino)methyl]pterostilbene (**3**)

**3** was obtained as yellow oil (169 mg, yield: 69 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.83(s, 1H, OH) 7.23 (d, *J* = 8.2 Hz, 1H, 6'-H), 7.03(s, 1H, 2'-H), 6.90 (d, *J* = 16.2 Hz, 1H, β-CH=), 6.76(d, *J* = 16.2 Hz, 1H, α-CH=), 6.73(d, *J* = 8.6 Hz, 1H, 5'-H), 6.54(s, 2H, 2-H and 6-H), 6.27 (s, 1H, 4-H), 3.71(s, 6H, 3-OCH<sub>3</sub> and 5-OCH<sub>3</sub>), 3.55(s, 2H, 3'-CH<sub>2</sub>N), 2.23(s, 6H, N(CH<sub>3</sub>)<sub>2</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) : δ 161.0, 158.3, 139.9, 129.0, 128.3, 127.3, 126.7, 125.8, 122.1, 116.4, 104.3, 99.4, 62.8, 55.3, 44.4; ESIMS *m/z*: 314 [M + H]<sup>+</sup>.

#### (*E*)-3'-[(Diethylamino)methyl]pterostilbene (**4**)

**4** was obtained as yellow oil (168 mg, yield 63 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.22 (d, *J* = 8.3 Hz, 1H, 6'-H), 7.03 (s, 1H, 2'-H), 6.90 (d, *J* = 16.2 Hz, 1H, β-CH=), 6.76 (d, *J* = 16.2 Hz, 1H, α-CH=), 6.70 (d, *J* = 8.3 Hz, 1H, 5'-H), 6.54(d, 2H, 2-H and 6-H), 6.27(s, 1H, 4-H), 3.71 (s, 6H, 3-OCH<sub>3</sub> and 5-OCH<sub>3</sub>), 3.68 (s, 2H, 3'-CH<sub>2</sub>N), 2.53(q, *J* = 6.8 Hz, 4H, 2CH<sub>2</sub>), 1.01 (t, *J* = 7.0 Hz, 6H,

2CH<sub>3</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) : δ 161.0, 158.6, 140.0, 129.1, 128.2, 127.0, 126.7, 125.6, 122.3, 116.4, 104.3, 99.4, 56.9, 55.3, 46.3, 11.2; ESIMS *m/z* 342 [M+H]<sup>+</sup>.

(*E*)-3'-(Piperidin-1-ylmethyl)pterostilbene (**5**)

**5** was obtained as white crystals (182 mg, yield 66 %), m.p. 80–81 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.35 (d, *J* = 7.6 Hz, 6'-H), 7.15 (s, 1H, 2'-H), 7.00 (d, *J* = 16.2 Hz, 1H, β-CH=), 6.86 (d, *J* = 16.2 Hz, 1H, α-CH=), 6.82 (s, 1H, 5'-H), 6.64 (s, 2H, 2-H and 6-H), 6.37 (d, *J* = 2.1 Hz, 1H, 4-H), 3.83 (s, 6H, 3-OCH<sub>3</sub> and 5-OCH<sub>3</sub>), 3.73 (s, 2H, 3'-CH<sub>2</sub>N), 2.57 (t, *J* = 2.3 Hz, 4H, NCH<sub>2</sub>), 1.69–1.65 (m, *J* = 5.0 Hz, 4H, 2CH<sub>2</sub>), 1.55–1.52 (m, *J* = 1.6 Hz, 2H, CH<sub>2</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) : δ 159.9, 157.2, 138.8, 128.0, 127.1, 126.0, 125.7, 124.6, 120.7, 115.3, 103.1, 98.3, 61.1, 54.3, 52.8, 24.8, 22.9; ESIMS *m/z* : 354 [M+H]<sup>+</sup>.

(*E*)-3'-[(4-Methylpiperazin-1-yl)methyl]pterostilbene (**6**)

**6** was obtained as yellow oil (184 mg, yield 64 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.26 (d, *J* = 8.3 Hz, 1H, 6'-H), 7.07 (s, 1H, 2'-H), 6.91 (d, *J* = 16.2 Hz, 1H, β-CH=), 6.82 (d, *J* = 16.2 Hz, 1H, α-CH=), 6.74 (d, *J* = 7.9 Hz, 1H, 5'-H), 6.56 (s, 2H, 2-H and 6-H), 6.29 (s, 1H, 4-H), 3.74 (s, 6H, 3-OCH<sub>3</sub> and 5-OCH<sub>3</sub>), 3.66 (s, 2H, 3'-CH<sub>2</sub>N), 2.80–2.27 (m, 8H, NCH<sub>2</sub>), 2.25 (s, 3H, NCH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) : δ 159.9, 156.7, 138.7, 127.8, 127.5, 126.3, 125.9, 124.9, 120.2, 115.4, 103.2, 98.4, 60.3, 54.3, 53.8, 51.3, 44.8; ESIMS *m/z*: 369 [M+H]<sup>+</sup>.

(*E*)-3'-(Pyrrolidin-1-ylmethyl)pterostilbene (**7**)

**7** was obtained as yellow oil (164 mg, yield 62 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.53 (s, 1H, OH), 7.35 (d, *J* = 8.3, 1.8 Hz, 1H, 6'-H), 7.18 (d, *J* = 1.3 Hz, 1H, 2'-H), 7.02 (d, *J* = 16.2 Hz, 1H, β-CH=), 6.89 (d, *J* = 16.2 Hz, 1H, α-CH=), 6.85 (d, *J* = 8.4 Hz, 1H, 5'-H), 6.66 (d, *J* = 2.1 Hz, 2H, 2-H and 6-H), 6.39 (d, *J* = 2.0 Hz, 1H, 4-H), 3.87 (d, *J* = 6.3 Hz, 2H, 3'-CH<sub>2</sub>N), 3.84 (s, 6H, 3-OCH<sub>3</sub> and 5-OCH<sub>3</sub>), 2.69 (s, 4H, N(CH<sub>2</sub>)<sub>2</sub>), 1.88 (s, 4H, 2CH<sub>2</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 160.8, 158.1, 139.8, 128.9, 128.1, 127.1, 126.3, 125.6, 122.3, 116.3, 104.1, 99.3, 58.5, 55.3, 53.4, 23.6; ESIMS *m/z*: 340 [M+H]<sup>+</sup>.

(*E*)-3', 5'-Bis[(4-methylpiperazin-1-yl)methyl]pterostilbene (**8**)

**8** was obtained as yellow oil (131 mg, yield 35 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.18 (s, 2H, 2'-H and 6'-H), 6.96 (d, *J* = 16.2 Hz, 1H, β-CH=), 6.83 (d, *J* = 16.2 Hz, 1H, α-CH=), 6.60 (d, *J* = 1.9 Hz, 2H, 2-H and 6-H), 6.32 (d, *J* = 1.7 Hz, 1H, 4-H), 3.78 (s, 6H, 3-OCH<sub>3</sub> and 5-OCH<sub>3</sub>),

3.62 (d, *J* = 4.3 Hz, 4H, 3'-CH<sub>2</sub>N and 5'-CH<sub>2</sub>N), 2.89–2.27 (m, 16H, NCH<sub>2</sub>), 2.25 (s, 6H, NCH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) : δ 160.8, 156.6, 139.8, 129.0, 127.7, 127.2, 125.7, 122.7, 104.1, 99.4, 58.8, 55.3, 54.9, 52.7, 45.9; ESIMS *m/z*: 481 [M+H]<sup>+</sup>.

(*E*)-3', 5'-Bis(morpholinomethyl)pterostilbene (**9**)

**9** was obtained as yellow oil (117 mg, yield 33 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.17 (s, 2H, 2'-H and 6'-H), 6.92 (d, *J* = 16.2 Hz, 1H, β-CH=), 6.80 (d, *J* = 16.2 Hz, 1H, α-CH=), 6.56 (s, 2H, 2-H and 6-H), 6.29 (s, 1H, 4-H), 3.74 (s, 6H, 3-OCH<sub>3</sub> and 5-OCH<sub>3</sub>), 3.67 (s, 8H, OCH<sub>2</sub>), 3.58 (s, 4H, 3'-CH<sub>2</sub>N and 5'-CH<sub>2</sub>N), 2.49 (s, 8H, NCH<sub>2</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) : δ 161.0, 156.2, 139.7, 128.8, 128.1, 127.7, 126.1, 122.3, 104.3, 99.5, 66.8, 59.3, 55.4, 53.2; ESIMS *m/z*: 455 [M+H]<sup>+</sup>.

(*E*)-3'-Methoxyl-5'-((dimethylamino)methyl)pterostilbene (**10**)

**10** was obtained as yellow oil (173 mg, yield 72 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.63 (s, 1H, OH), 6.99 (s, 1H, 6'-H), 6.97 (d, *J* = 16.2 Hz, 1H, β-CH=), 6.86 (d, *J* = 16.2 Hz, 1H, α-CH=), 6.75 (s, 1H, 2'-H), 6.64 (d, *J* = 2.1 Hz, 2H, 2-H and 6-H), 6.36 (d, *J* = 2.1 Hz, 1H, 4-H), 3.93 (s, 3H, 3'-OCH<sub>3</sub>), 3.81 (s, 6H, 3-OCH<sub>3</sub> and 5-OCH<sub>3</sub>), 3.66 (s, 2H, 5'-CH<sub>2</sub>N), 2.34 (s, 6H, NCH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) : δ 160.8, 148.0, 147.6, 139.6, 129.1, 127.9, 125.8, 121.9, 119.4, 108.7, 104.1, 99.4, 62.5, 55.8, 55.2, 44.4; EIMS *m/z*: 343 [M]<sup>+</sup>.

(*E*)-3'-Methoxyl-5'-((diethylamino)methyl)pterostilbene (**11**)

**11** was obtained as yellow oil (189 mg, yield 73 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) : δ 6.90 (s, 1H, 6'-H), 6.89 (d, *J* = 16.2 Hz, β-CH=), 6.78 (d, 1H, *J* = 16.2 Hz, α-CH=), 6.67 (s, 1H, 2'-H), 6.56 (d, *J* = 2.1 Hz, 2H, 2-H and 6-H), 6.29 (t, *J* = 2.1 Hz, 1H, 4-H), 3.85 (s, 3H, 3'-OCH<sub>3</sub>), 3.74 (s, 6H, 3-OCH<sub>3</sub> and 5-OCH<sub>3</sub>), 3.71 (s, 2H, 5'-CH<sub>2</sub>N), 2.56 (q, *J* = 6.1 Hz, 4H, NCH<sub>2</sub>), 1.04 (t, *J* = 6.2 Hz, 6H, 2CH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 160.8, 148.4, 147.9, 139.6, 129.4, 127.8, 125.8, 121.5, 119.6, 108.4, 104.1, 99.4, 56.0, 55.7, 55.2, 46.2, 11.0; EIMS *m/z* : 371 [M]<sup>+</sup>.

(*E*)-3'-Methoxyl-5'-(piperidin-1-yl methyl)pterostilbene (**12**)

**12** was obtained as yellow oil (185 mg, yield 69 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.90 (s, 1H, 6'-H), 6.89 (d, *J* = 16.2 Hz, β-CH=), 6.77 (d, *J* = 16.2 Hz, 1H, α-CH=), 6.65 (d, *J* = 1.5 Hz, 1H, 2'-H), 6.56 (d, *J* = 2.2 Hz, 2H,



2-H and 6-H), 6.28 (d,  $J = 2.2$  Hz, 1H, 4-H), 3.84 (s, 3H, 3'-OCH<sub>3</sub>), 3.72 (s, 6H, 3-OCH<sub>3</sub> and 5-OCH<sub>3</sub>), 3.59 (s, 2H, 5'-CH<sub>2</sub>N), 2.60–2.26 (m, 4H, NCH<sub>2</sub>), 1.59–1.52 (m, 4H, CH<sub>2</sub>), 1.40 (s, 2H, CH<sub>2</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) :  $\delta$  160.8, 147.9, 147.6, 139.6, 129.6, 127.7, 125.6, 121.4, 119.4, 108.4, 104.0, 99.3, 61.8, 55.7, 55.4, 53.7, 25.7, 23.8; EIMS  $m/z$ : 383 [M]<sup>+</sup>.

(*E*)-3'-Methoxyl-5'-[(4-methylpiperazin-1-yl)methyl] pterostilbene (**13**)

**13** was obtained as yellow oil (173 mg, yield 62 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  6.99 (s, 1H, 6'-H), 6.98 (d,  $J = 16.2$  Hz, 1H,  $\beta$ -CH=), 6.86 (d,  $J = 16.2$  Hz, 1H,  $\alpha$ -CH=), 6.78 (d,  $J = 1.4$  Hz, 1H, 2'-H), 6.64 (d,  $J = 2.2$  Hz, 2H, 2-H and 6-H), 6.37 (t,  $J = 2.2$  Hz, 1H, 4-H), 3.94 (s, 3H, 3'-OCH<sub>3</sub>), 3.83 (s, 6H, 3-OCH<sub>3</sub> and 5-OCH<sub>3</sub>), 3.75 (s, 2H, 5'-CH<sub>2</sub>N), 2.88–2.35 (m, 8H, NCH<sub>2</sub>), 2.32 (s, 3H, NCH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) :  $\delta$  160.9, 148.1, 147.2, 139.7, 129.1, 128.2, 126.1, 121.1, 119.6, 108.7, 104.4, 99.5, 61.0, 55.9, 55.3, 54.8, 52.3, 45.7; EIMS  $m/z$  : 398 [M]<sup>+</sup>.

(*E*)-3'-Methoxyl-5'-(pyrrolidin-1-ylmethyl) pterostilbene (**14**)

**14** was obtained as yellow oil (173 mg, yield 67 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) :  $\delta$  6.90 (s, 1H, 6'-H), 6.89 (d,  $J = 16.2$  Hz,  $\beta$ -CH=), 6.78 (d,  $J = 16.2$  Hz, 1H,  $\alpha$ -CH=), 6.68 (s, 1H, 2'-H), 6.56 (d,  $J = 2.1$  Hz, 2H, 2-H and 6-H), 6.29 (s, 1H, 4-H), 3.85 (s, 3H, 3'-OCH<sub>3</sub>), 3.77 (s, 2H, 5'-CH<sub>2</sub>N), 3.74 (s, 6H, 3-OCH<sub>3</sub> and 5-OCH<sub>3</sub>), 2.66–2.49 (m, 4H, NCH<sub>2</sub>), 1.79–1.74 (m, 4H, CH<sub>2</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) :  $\delta$  159.9, 147.1, 146.5, 138.7, 128.2, 127.1, 125.0, 120.4, 118.6, 107.7, 103.3, 98.5, 60.2, 55.0, 54.3, 49.1, 33.0; EIMS  $m/z$ : 369 [M]<sup>+</sup>.

(*E*)-3'-Methoxyl-5'-(morpholinomethyl) pterostilbene (**15**)

**15** was obtained as yellow oil (199 mg, yield 74 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  6.91 (s, 1H, 6'-H), 6.90 (d,  $J = 16.2$  Hz, 1H,  $\beta$ -CH=), 6.79 (d,  $J = 16.2$  Hz, 1H,  $\alpha$ -CH=), 6.69 (s, 1H, 2'-H), 6.56 (d,  $J = 2.1$  Hz, 2H, 2-H and 6-H), 6.29 (t,  $J = 2.1$  Hz, 1H, 4-H), 3.85 (s, 3H, 3'-OCH<sub>3</sub>), 3.74 (s, 6H, 3-OCH<sub>3</sub> and 5-OCH<sub>3</sub>), 3.68 (s, 2H, 5'-CH<sub>2</sub>N), 3.67 (t,  $J = 4.2$  Hz, 4H, NCH<sub>2</sub>), 2.52 (s, 4H, OCH<sub>2</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) :  $\delta$  160.9, 148.0, 146.9, 139.5, 129.0, 128.4, 126.1, 120.7, 119.7, 108.8, 104.2, 99.5, 66.7, 61.5, 55.8, 55.1, 52.8; EIMS  $m/z$  : 385 [M]<sup>+</sup>.

(*E*)-3'-Methoxyl-5'-(piperidin-4-ol-1-ylmethyl) pterostilbene (**16**)

**16** was obtained as yellow oil (170 mg, yield 61 %). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  6.98 (d,  $J = 16.2$  Hz, 1H,  $\beta$ -CH=), 6.97 (s, 1H, 6'-H), 6.86 (d,  $J = 16.2$  Hz, 1H,  $\alpha$ -CH=), 6.75 (d,  $J = 1.2$  Hz, 1H, 2'-H), 6.64 (d,  $J = 2.2$  Hz, 2H, 2-H and 6-H), 6.37 (t,  $J = 2.1$  Hz, 1H, 4-H), 3.93 (s, 3H, 3'-OCH<sub>3</sub>), 3.82 (s, 6H, 3-OCH<sub>3</sub> and 5-OCH<sub>3</sub>), 3.72 (s, 2H, 5'-CH<sub>2</sub>N), 3.68–3.65 (m, 1H, CH-O), 2.86–2.37 (m, 4H, NCH<sub>2</sub>), 1.93–1.60 (m, 4H, 2CH<sub>2</sub>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) :  $\delta$  160.8, 147.9, 147.4, 139.6, 129.4, 127.9, 125.8, 122.0, 119.2, 108.3, 104.1, 99.4, 58.0, 55.8, 55.2, 53.3, 29.8, 23.5; EIMS  $m/z$  : 399 [M]<sup>+</sup>.

### Assay for antiproliferative activity

The CCK-8 reagent solution (10 %, 10  $\mu$ L) was added to each well of a 96-well microtiter plate containing  $5 \times 10^3$  cells (Hela), then different concentrations of compounds **1–16** (100, 25, 6.25, 1.56, 0.39, 0.0976, 0.0244, 0.0061  $\mu$ M) were added and incubated for 48 h [18]. Absorbance was measured at 450 ~ 490 nm using a microplate reader. A dose-response curve was plotted for each compound, and the half maximal inhibitory concentration (IC<sub>50</sub>) for cancer cell lines was recorded.

**Acknowledgments** We thank the National Natural Science Foundation of China (No. J1210040) and the Hunan Provincial Natural Science Foundation of China (No. 14JJ2048) for financial support.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

### References

- Rimando AM, Cuendet M, Desmarchelier C, Mehta RG, Pezzuto JM, Duke SO (2002) Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. *J Agric Food Chem* 50:3453–3457. doi:10.1021/jf0116855
- Pan MH, Chang YH, Badmaev V, Nagabhushanam K, Ho CT (2007) Pterostilbene induces apoptosis and cell cycle arrest in Human gastric carcinoma cells. *J Agric Food Chem* 55:7777–7785. doi:10.1021/jf071520h
- Ko HS, Kim JS, Cho SM, Cho SM, Lee HJ, Ahn KS, Kim SH, Lee EO (2014) Urokinase-type plasminogen activator expression and Rac1/WAVE-2/Arp2/3 pathway are blocked by pterostilbene to suppress cell migration and invasion in MDA-MB-231 cells. *Bioorg Med Chem Lett* 24:1176–1179. doi:10.1016/j.bmcl.2013.12.115
- Chen RJ, Tsai SJ, Ho CT, Pan MH, Ho YS, Wu CH, Wang YJ (2012) Chemopreventive effects of pterostilbene on urethane-induced lung carcinogenesis in mice via the inhibition of EGFR-mediated path-

- ways and the induction of apoptosis and autophagy. *J Agric Food Chem* 60:11533–11541. doi:[10.1021/jf302778a](https://doi.org/10.1021/jf302778a)
5. Gill MT, Bajaj R, Chang CJ, Nichols DE, McLaughlin JL (1987) 3,3',5'-Tri-*O*-methylpiceatannol and 4,3',5'-tri-*O*-methylpiceatannol: improvements over piceatannol in bioactivity. *J Nat Prod* 50:36–40. doi:[10.1021/np50049a006](https://doi.org/10.1021/np50049a006)
  6. Singh SK, Ruchelman AL, Li TK, Li TK, Liu A, Liu LF, LaVoie EJ (2003) Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)-2,3-methylenedioxy-5H-dibenzo-[c, h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity. *J Med Chem* 46:2254–2257. doi:[10.1021/jm020498a](https://doi.org/10.1021/jm020498a)
  7. Zhu S, Ruchelman AL, Zhou N, Liu A, Liu LF, Lavioe EJ (2006) 6-Substituted 6H-dibenzo[c, h][2,6]naphthyridin-5-ones: reversed lactam analogues of ARC-111 with potent topoisomerase I-targeting activity and cytotoxicity. *Bioorg Med Chem* 14:3131–3143. doi:[10.1016/j.bmc.2005.12.028](https://doi.org/10.1016/j.bmc.2005.12.028)
  8. Liu T, Xu Z, He Q, Chen Y, Yang B, Hu Y (2007) Nitrogen-containing flavonoids as CDK1/Cyclin B inhibitors: design, synthesis, and biological evaluation. *Bioorg Med Chem Lett* 17:278–281. doi:[10.1016/j.bmcl.2006.07.088](https://doi.org/10.1016/j.bmcl.2006.07.088)
  9. Tonelli M, Tasso B, Mina L, Paglietti G, Boido V, Sparatore F (2013) Primary antiproliferative activity evaluation of 1-(quinolizidin-1'-yl)methyl and 1-( $\omega$ -tert-amino)alkyl-substituted 2-phenyl-, 2-benzyl- and 2-[(benzotriazol-1/2-yl)methyl]benzimidazoles on human cancer cell lines. *Mol Divers* 17:409–419. doi:[10.1007/s11030-013-9440-3](https://doi.org/10.1007/s11030-013-9440-3)
  10. Liu HR, Huang XQ, Lou DH, Liu X, Liu WK, Wang QA (2014) Synthesis and acetylcholinesterase inhibitory activity of Mannich base derivatives flavokawain B. *Bioorg Med Chem Lett* 24:4749–4753. doi:[10.1016/j.bmcl.2014.07.087](https://doi.org/10.1016/j.bmcl.2014.07.087)
  11. Joshi D, Field J, Murphy J, Abdelrahim M, Schönherr H, Sparrow JR, Ellestad G, Nakanishi K, Zask A (2013) Synthesis of antioxidants for prevention of age-related macular degeneration. *J Nat Prod* 76:450–454. doi:[10.1021/np300769c](https://doi.org/10.1021/np300769c)
  12. Lu C, Guo Y, Li J, Yao M, Liao Q, Xie Z, Li X (2012) Design, synthesis, and evaluation of resveratrol derivatives as A $\beta$ <sub>1–42</sub> aggregation inhibitors, antioxidants, and neuroprotective agents. *Bioorg Med Chem Lett* 22:7683–7687. doi:[10.1016/j.bmcl.2012.09.105](https://doi.org/10.1016/j.bmcl.2012.09.105)
  13. Paul S, Rimando AM, Lee HJ, Lee HJ, Ji Y, Reddy BS, Suh N (2009) Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. *Cancer Prev Res* 2:650–657. doi:[10.1158/1940-6207.CAPR-08-0224](https://doi.org/10.1158/1940-6207.CAPR-08-0224)
  14. Mizuno CS, Ma G, Khan S, Patny A, Avery MA, Rimando AM (2008) Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPAR $\alpha$ . *Bioorg Med Chem* 16:3800–3808. doi:[10.1016/j.bmc.2008.01.051](https://doi.org/10.1016/j.bmc.2008.01.051)
  15. Wang GQ, Chen YL, Han MS, Sun L, Wang QA (2011) Synthesis and biological activity of pterostilbene and 3-methoxy pterostilbene and their glucosides derivatives. *Chin J Org Chem* 31:2114–2120
  16. Bhupesh SS, Nyaradzai N (2012) A novel microwave synthesis of quinoline-3-carboxylic acid derivatives for treatment against human African trypanosomiasis. *Mol Divers* 16:685–695. doi:[10.1007/s11030-012-9401-2](https://doi.org/10.1007/s11030-012-9401-2)
  17. Peng YQ, Dou RL, Song GH (2005) Dramatically accelerated synthesis of  $\beta$ -aminoketones via aqueous mannich reaction under combined microwave and ultrasound irradiation. *Synlett* 14:2245–2247
  18. Hideyuki T, Munetaka I, Fumio O, Kazumi S, Tomoyuki H, Keiji S, Masami W (1999) A water-soluble tetrazolium salt useful for colorimetric cell viability assay. *Anal Commun* 36:47–50. doi:[10.1039/A809656B](https://doi.org/10.1039/A809656B)